Drugs / EP1090
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00532974 | Oct 2006 → Apr 2008 | HIV infectious disease | Epimmune | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP1090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00532974 ↗ |
| Known as | EP HIV-1090 | “Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090)” NCT00532974 ↗ |
| Modality | Vaccine | “DNA Vaccine” NCT00532974 ↗ |